Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection
…, MR Holbrook, J Kindrachuk, RF Johnson… - Antimicrobial agents …, 2014 - Am Soc Microbiol
Outbreaks of emerging infections present health professionals with the unique challenge of
trying to select appropriate pharmacologic treatments in the clinic with little time available for …
trying to select appropriate pharmacologic treatments in the clinic with little time available for …
Antiviral potential of ERK/MAPK and PI3K/AKT/mTOR signaling modulation for Middle East respiratory syndrome coronavirus infection as identified by temporal …
…, MB Frieman, D Traynor, RF Johnson… - Antimicrobial agents …, 2015 - Am Soc Microbiol
Middle East respiratory syndrome coronavirus (MERS-CoV) is a lineage C betacoronavirus,
and infections with this virus can result in acute respiratory syndrome with renal failure. …
and infections with this virus can result in acute respiratory syndrome with renal failure. …
Interferon-β and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays
…, H Zhou, J Kindrachuk, RF Johnson… - Journal of general …, 2014 - microbiologyresearch.org
The Middle East respiratory syndrome coronavirus (MERS-CoV) presents a novel emerging
threat to public health worldwide. Several treatments for infected individuals have been …
threat to public health worldwide. Several treatments for infected individuals have been …
Contribution of Ebola virus glycoprotein, nucleoprotein, and VP24 to budding of VP40 virus-like particles
JM Licata, RF Johnson, Z Han, RN Harty - Journal of virology, 2004 - Am Soc Microbiol
The VP40 matrix protein of Ebola virus buds from cells in the form of virus-like particles (VLPs)
and plays a central role in virus assembly and budding. In this study, we utilized a …
and plays a central role in virus assembly and budding. In this study, we utilized a …
[HTML][HTML] Middle East respiratory syndrome and severe acute respiratory syndrome: current therapeutic options and potential targets for novel therapies
J Dyall, R Gross, J Kindrachuk, RF Johnson… - Drugs, 2017 - Springer
No specific antivirals are currently available for two emerging infectious diseases, Middle East
respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS). A literature …
respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS). A literature …
[HTML][HTML] Real-time sequence-validated loop-mediated isothermal amplification assays for detection of Middle East respiratory syndrome coronavirus (MERS-CoV)
The Middle East respiratory syndrome coronavirus (MERS-CoV), an emerging human
coronavirus, causes severe acute respiratory illness with a 35% mortality rate. In light of the recent …
coronavirus, causes severe acute respiratory illness with a 35% mortality rate. In light of the recent …
Exposure to lung-migrating helminth protects against murine SARS-CoV-2 infection through macrophage-dependent T cell activation
…, NL Garza, BAP Lafont, RF Johnson… - Science …, 2023 - science.org
Helminth endemic regions report lower COVID-19 morbidity and mortality. Here, we show
that lung remodeling from a prior infection with a lung-migrating helminth, Nippostrongylus …
that lung remodeling from a prior infection with a lung-migrating helminth, Nippostrongylus …
A single intranasal dose of a live-attenuated parainfluenza virus-vectored SARS-CoV-2 vaccine is protective in hamsters
…, IN Moore, S Afroz, RF Johnson… - Proceedings of the …, 2021 - National Acad Sciences
Single-dose vaccines with the ability to restrict SARS-CoV-2 replication in the respiratory tract
are needed for all age groups, aiding efforts toward control of COVID-19. We developed a …
are needed for all age groups, aiding efforts toward control of COVID-19. We developed a …
Human polyclonal immunoglobulin G from transchromosomic bovines inhibits MERS-CoV in vivo
…, JH Kuhn, MR Holbrook, RF Johnson… - Science translational …, 2016 - science.org
As of 13 November 2015, 1618 laboratory-confirmed human cases of Middle East respiratory
syndrome coronavirus (MERS-CoV) infection, including 579 deaths, had been reported to …
syndrome coronavirus (MERS-CoV) infection, including 579 deaths, had been reported to …
[HTML][HTML] Non-neutralizing antibodies elicited by recombinant Lassa–Rabies vaccine are critical for protection against Lassa fever
…, PB Jahrling, G Tan, C Wirblich, RF Johnson… - Nature …, 2018 - nature.com
Lassa fever (LF), caused by Lassa virus (LASV), is a viral hemorrhagic fever for which no
approved vaccine or potent antiviral treatment is available. LF is a WHO priority disease and, …
approved vaccine or potent antiviral treatment is available. LF is a WHO priority disease and, …
